Mona Mangat, MD
Allergy & Immunology · St Petersburg, FLNPI 1972671824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 429 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,629, 2.5 times the $662 reported in 2019.
Across 429 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$906
- CSL Behring$898
- Regeneron Healthcare Solutions, Inc.$830
- Sanofi$522
- Amgen$453
- plus $3K from 28 others
Across 4 payments — averaging $1709.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$7K
What the payments were for
- Food & beverage$7,33195%
- Education$3625%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 95 | $1,426 |
| AstraZeneca | 49 | $906 |
| CSL Behring | 42 | $898 |
| Regeneron Healthcare Solutions, Inc. | 39 | $830 |
| Sanofi | 25 | $522 |
| Amgen(2 entities) | 23 | $453 |
| Novartis | 22 | $446 |
| Pfizer | 41 | $390 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $295 |
| Kaleo, Inc. | 11 | $179 |
| Genentech USA, Inc. | 7 | $135 |
| AbbVie | 6 | $133 |
| Sanofi-aventis U.S. LLC | 2 | $117 |
| Optinose US, Inc. | 7 | $114 |
| Ionis Pharmaceuticals, Inc. | 4 | $90 |
| Biocryst US Sales Co., LLC | 4 | $85 |
| Covis Pharma GmbH | 4 | $83 |
| Incyte Corporation | 4 | $73 |
| Shire North American Group Inc | 4 | $73 |
| Galderma Laboratories, L.p. | 3 | $56 |
| Pharming Healthcare, Inc. | 2 | $53 |
| Octapharma USA, Inc. | 2 | $53 |
| Hikma Pharmaceuticals USA | 3 | $45 |
| Azurity Pharmaceuticals, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Tersera Therapeutics LLC | 1 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| LEO Pharma Inc. | 1 | $22 |
| Merck | 1 | $21 |
| GC Biopharma USA, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Organon | 1 | $2 |
How this compares
$7,694 in reported general payments places this provider in the 55th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $77,509 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $53,869 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $34,498 |
| Arnuity ElliptaFluticasone Furoate | 63 | $20,265 |
| Spiriva RespimatTiotropium Bromide | 21 | $14,530 |
| Epinephrine | 60 | $8,745 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $7,731 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $5,796 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,092 |
| Fluticasone Propionate | 183 | $3,485 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $3,346 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $3,326 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,140 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $2,144 |
| Levocetirizine Dihydrochloride | 120 | $1,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,426 | $132,272199 claims |
| CSL BehringHizentra | $898 | $53,86913 claims |
| Boehringer IngelheimSpiriva Respimat | $18 | $14,53021 claims |
| Hikma Pharmaceuticals USAEpinephrine | $45 | $8,74560 claims |
| AstraZenecaSymbicort | $906 | $7,73114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in St Petersburg
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.